Cancer Drug Reimbursement Based On “Value Threshold” Proposed At IoM Workshop
This article was originally published in The Pink Sheet Daily
Wharton economist Danzon proposes that private payers establish a “value threshold” for cancer drugs based on an outcomes assessment by an independent agency to determine reimbursement.
You may also be interested in...
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.
As interest in immune/inflammatory disease increases and savings achieved dip, payer focus on patient-reported outcomes for contracts reflects shift in focus, Avalere survey suggests.
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.